A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.
The SARS-CoV-2 main protease (Mpro) is a major therapeutic target. The Mpro inhibitor, nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID-19. As Mpro inhibitor use increases, drug resistant mutations will likely emerge. We have established a non-pathogenic...
Main Authors: | Jin Ou, Eric M Lewandowski, Yanmei Hu, Austin A Lipinski, Ali Aljasser, Mariliz Colon-Ascanio, Ryan T Morgan, Lian M C Jacobs, Xiujun Zhang, Melissa J Bikowitz, Paul R Langlais, Haozhou Tan, Jun Wang, Yu Chen, John S Choy |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-08-01
|
Series: | PLoS Pathogens |
Online Access: | https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1011592&type=printable |
Similar Items
-
Naturally Occurring Mutations of SARS-CoV‑2 Main Protease Confer Drug Resistance to Nirmatrelvir
by: Yanmei Hu, et al.
Published: (2023-07-01) -
Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
by: Karen Anbro Gammeltoft, et al.
Published: (2023-09-01) -
Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
by: Srijan Chatterjee, et al.
Published: (2023-06-01) -
A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid
by: Joseph R. A. Kincaid, et al.
Published: (2022-11-01) -
Exploring the structural and molecular interaction landscape of nirmatrelvir and Mpro complex: The study might assist in designing more potent antivirals targeting SARS-CoV-2 and other viruses
by: Chiranjib Chakraborty, et al.
Published: (2023-12-01)